Strategies to target MTAP deletion, KRAS G12D and ESR1 mutations, and CDK4 and CDK2 further expand the landscape of precision oncology

Data from studies presented highlight the importance of integrating and incorporating comprehensive genomic profiling into clinical practice across a broad range of tumour types

However, the future of TKI combinations for these rare tumours is uncertain

New data from the ALINA study confirm lack of influence of EML4-ALK variant on outcome in this patient population 

Study findings indicate that the agent is promising as maintenance therapy, but managing its tolerability presents challenges  

Several studies report on promising data with immunomodulation and alternative approaches

Final results from the KEYNOTE-522 study confirm that the integration of pembrolizumab into the treatment regimen has the potential to transform patient management, but careful patient selection and monitoring for toxicities will be crucial 

Results from the Neo-CheckRay study report an acceptable toxicity profile with the addition of a PD-L1 inhibitor to neoadjuvant chemotherapy and stereotactic body radiation therapy  

Findings from two studies show high rates of complete remissions in patients with Bacillus Calmette-Guérin unresponsive high-risk non-muscle-invasive bladder cancer and muscle-invasive bladder cancer 

Early-phase clinical trial results show promise to optimise the current standard of care by using dual-targeting agents and investigating the most effective chemotherapy backbone for PD-L1 blockade